EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis

Tsutomu Takeuchi iD, Megumi Nakanishi, Masafumi Kawanishi iD, Hironori Yamasaki, Yoshiya Tanaka iD

Modern Rheumatology · 06.07.2024 · 34 (4) · 678-685

DOI: 10.1093/mr/road097 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, online erschienen am 07.10.2023. Verfasst von Tsutomu Takeuchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This article aims to evaluate the effect of the extended dosing interval on the efficacy and safety of ozoralizumab in patients with rheumatoid arthritis (RA).

Methods

In a long-term extension study (HOSHIZORA trial) for patients who had completed a phase II/III study with methotrexate or a phase III study without methotrexate, the dosing interval of ozoralizumab was allowed to extend from every 4 weeks (Q4W) to every 8 weeks (Q8W), at the physician’s discretion, for patients who had maintained a 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) <3.2 at the last two time points. The continuation rate, efficacy, and safety were examined in patients who had completed 24 weeks after the change in the dosing interval by the data cut-off point.

Results

Of the 32 patients who maintained DAS28-ESR <3.2 and changed the interval from Q4W to Q8W, 28 (87.5%) remained on Q8W for 24 weeks. At Week 24, the percentages of patients who remained on Q8W and achieved DAS28-ESR <2.6 and <3.2 were 71.9% and 84.4%, respectively. No safety concerns were observed for 24 weeks in the Q8W group.

Conclusions

In patients with RA and maintained DAS28-ESR <3.2 with ozoralizumab, efficacy was sustained and well tolerated after the dosing interval was extended from Q4W to Q8W.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHumansFemaleMaleMiddle AgedTreatment OutcomeAgedAntibodies, Monoclonal, HumanizedDrug Administration ScheduleAdultSeverity of Illness IndexSingle-Domain AntibodiesTumor Necrosis Factor-alphaMethotrexate

Stichwörter der Autor:innen

OzoralizumabVHH antibodyrheumatoid arthritistaperingtumour necrosis factor-α inhibitor

Substanzen

Antirheumatic AgentsAntibodies, Monoclonal, HumanizedSingle-Domain AntibodiesTumor Necrosis Factor-alphaMethotrexate

Autor:innen und Institutionen

  • Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan.
  • Keio University School of Medicine, Tokyo, Japan.
  • Development Headquarters, Taisho Pharmaceutical Co., Ltd, Tokyo, Japan.
  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.

ORCID-Profile: Tsutomu Takeuchi, Masafumi Kawanishi, Yoshiya Tanaka

Zitieren

APA

Takeuchi, T., Nakanishi, M., Kawanishi, M., Yamasaki, H., & Tanaka, Y. (2024). Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Modern Rheumatology, 34(4), 678-685. https://doi.org/10.1093/mr/road097

Vancouver

Takeuchi T, Nakanishi M, Kawanishi M, Yamasaki H, Tanaka Y. Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Modern Rheumatology. 2024;34(4):678-685. doi:10.1093/mr/road097

BibTeX
@article{Takeuchi2024,
  author = {Takeuchi, Tsutomu and Nakanishi, Megumi and Kawanishi, Masafumi and Yamasaki, Hironori and Tanaka, Yoshiya},
  title = {Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis},
  journal = {Modern Rheumatology},
  year = {2024},
  volume = {34},
  number = {4},
  pages = {678--685},
  doi = {10.1093/mr/road097}
}
Kostenlos starten →